Purpose: To evaluate the long-term intraocular pressure (IOP)-lowering effect and safety parameters following treatment with two trabecular micro-bypass stents and topical prostaglandin in phakic eyes with open-angle glaucoma (OAG) not controlled on two preoperative medications.
Purpose: To obtain pilot data on posture-induced changes of intraocular pressure (IOP), systemic pressure, and pattern electroretinogram (PERG) predictive of future optic nerve tissue loss glaucoma suspects (GSs).
Methods: Mean peripapillary retinal fiber layer thickness (RNFLT) was measured with optical coherence tomography 2 times/year in 28 GS aged 58+/-8.9 years over 5.0+/-0.73 years. All patients had a baseline PERG, IOP, and brachial blood pressure measurements in the seated and -10 degrees head-down-body-tilt (HDT) position. Outcome measures were seated/HDT PERG amplitude and phase, IOP, mean arterial blood pressure, and estimated ocular perfusion pressure. An additional group of 11 similarly aged controls aged 56.9+/-13 years was tested for comparison.
Results: Although all GS had initial RNFLT in the normal range, 9/28 of them developed significant (P<0.05) loss of mean RNFLT [thinners (T)] over the follow-up period as opposed to 19/28 who did not [nonthinners (NT)]. Significant (P<0.05) differences between similarly aged controls, NT, and T were found in PERG amplitude, PERG phase, mean arterial blood pressure, IOP, and ocular perfusion pressure. A nominal logistic regression using baseline PERG and hemodynamic variables was able to distinguish T from NT with an area under receiving operator characteristic of 0.89 (SE, 0.07).
Conclusions: Baseline PERG, IOP, and systemic blood pressure, together with their changes upon HDT, may have predictive value for future loss of optic nerve tissue in GS. This study supports the rationale for a full-scale clinical trial to identify patients at high risk of development of glaucoma.
Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.
Inder Paul Singh, MD, says the iStent (Glaukos) helps physicians reduce medication burden. He provides details on outcomes and discusses why safety makes this device advantageous for surgeons. Dr. Singh also explains how the iStent has improved the overall efficiency of his cataract surgery cases
We reviewed the current literature on the ability of micro-perimetry to detect non-neovascular age-related macular degeneration (AMD) disease progression. The index test was retinal sensitivity mea-surement assessed by microperimetry and comparators were other func-tional measures (best-corrected and low-luminance visual acuities, and fixation stability) and structural parameters [retinal thickness, choroidal thickness, and area of geographic atrophy (GA) determined by color fun-dus photographs, short-wave or near-infrared fundus autofluorescence].
Glaucoma is currently the second leading cause of blindness throughout the world. The goal of glaucoma treatment is to stop or slow disease progression. Current glaucoma medications achieve this almost exclusively through reduction of intraocular pressure (IOP). Unfortunately, even with appropriate use of currently available medications, many people with glaucoma will still experience vision loss. Intraocular pressure is the only known modifiable risk factor for patients with glaucoma, so improvements in patient outcomes rely on tight IOP control and patient adherence to therapy. In this educational activity, leading clinicians review established and new therapeutic agents for patients with glaucoma, including the recent clinical evidence for their safety and efficacy. In addition, discussion will comprise the recent evidence concerning the effects of low perfusion pressure on glaucoma development and progression
A 25-year-old woman with myopia who had an AC pIOL implantation in the left eye and posterior chamber pIOL implantation in the right eye developed bilateral granulomatous panuveitis 2 months after the second surgery. Physical examination showed bilateral Koeppe and Busacca nodules. Fluorescein angiography showed diffuse vascular and retinal pigment epithelial leakage in both eyes. With assessment of sympathetic ophthalmia, treatment with a high-dose systemic steroid was started. Oral cyclosporine and azathioprine were later added.
Для начисления зачетных единиц, полученных после прохождения обучения в рамках учебного мероприятия (конференция, мастер-класс, заседание профессионального общества), Вам необходимо указать индивидуальный код подтверждения на сайте Координационного совета по развитию непрерывного медицинского и фармацевтического образования Министерства здравоохранения РФ: http://www.sovetnmo.ru.
1. Лечащий врач по согласованию с руководителем медорганизации может отказаться лечить пациента, если отказ не угрожает жизни больного
2. Решение об отказе нужно передать пациенту либо отправить заказным письмом с уведомлением
3. Если все врачи отказались от наблюдения пациента по предусмотренной законом процедуре, руководитель может предложить гражданину обратиться в иную медорганизацию
Рекомендации детально объясняют публикационный процесс, процедуры рецензирования и опубликования, а также общепринятые требования к структуре научной статьи.
Данная информация нацелена на помощь научным работникам и повышение их публикационной активности.
Purpose: The aim was to evaluate the safety of bilateral same-day injections with intravitreal antiangiogenic drugs for macular diseases.
Methods: Cross-sectional retrospective review of unilateral and bilateral same-day antiangiogenic injections was conducted between January 2011 and March 2016 in the Unit of Macula, University and Polytechnic Hospital La Fe (Valencia, Spain). A total of 8,172 injections were administered, among which 6,560 were unilateral and 1,612 were bilateral injections. Patients were included in the study regardless of the diagnosis. Ranibizumab and aflibercept were the antiangiogenic drugs used. The presence of endophthalmitis or retinal detachment was evaluated.
Glaucoma is currently the second leading cause of blindness throughout the world. The goal of glaucoma treatment is to stop or slow disease progression. Current glaucoma medications achieve this almost exclusively through reduction of intraocular pressure (IOP). Unfortunately, even with appropriate use of currently available medications, many people with glaucoma will still experience vision loss. Intraocular pressure is the only known modifiable risk factor for patients with glaucoma, so improvements in patient outcomes rely on tight IOP control and patient adherence to therapy. In this educational activity, leading clinicians review established and new therapeutic agents for patients with glaucoma, including the recent clinical evidence for their safety and efficacy. In addition, discussion will comprise the recent evidence concerning the effects of low perfusion pressure on glaucoma development and progression.
The Scientific Committee invites you to participate actively in this congress which will be an extraordinary occasion for the exchange of thoughts and experiences. We look forward to receiving abstracts for consideration and inclusion in the program as oral or poster presentations.
Management of the geographic atrophy seen in late-stage dry age-related macular degeneration (AMD) poses several challenges. Scientific understanding of geographic atrophy continues to develop, and recent changes have been made to how this condition is classified, which underscores the importance of accurately monitoring progression. Although no treatment has been approved to manage late-stage dry AMD, complement inhibition, visual cycle modulation, neuroprotection, and stem cell therapy have had encouraging results in clinical trials
Purpose: To systematically review anatomical and functional outcomes subsequent to switching from bevacizumab/ranibizumab to aflibercept monotherapy in patients with treatment-resistant neovascular age-related macular degeneration (nAMD).
Сайт основан 20 декабря 2000 года
Авторские права на дизайн и всю информацию веб-сайта www.eyenews.ru (www.glaucomanews.ru www.corneanews.ru, www.cataractanews.ruwww.retinanews.ru www.айньюс.рф www.hrtclubrussia.ru), а также на подбор и расположение материалов принадлежат учредителю и редакции вышеуказаных порталов. Использование материалов сайтов разрешено только с письменного разрешения учредителя и редакции вышеуказанных сайтов. Воспроизведение фотографий, статей и новостей, абстрактов и прочего контента любым способом без письменного разрешения запрещено и влечет ответственность, предусмотренную законодательством о защите авторских прав. Запрещается автоматизированное извлечение информации сайта любыми сервисами без официального разрешения учредителя либо редакции сайтов. При цитировании материалов ссылка наwww.eyenews.ru и другие вышеуказанные сайты обязательна.